Leadership Team
Meet our experienced team.
ADC Linker & Conjugation Summit, August 20-22, 2024, in Boston, MA
Join us at the Abzena booth to discuss the crucial role of linker payload architecture in the successful design of your drug candidate. Meet Rebecca Goydel, PhD, our Scientific Director of Business Development, and learn how our expertise in mAbs, linkers, and payloads can help you create a robust lead drug candidate. Discover how we can assist you in developing a safe and effective ADC drug by seamlessly integrating the desired linker, payload, and monoclonal antibody (mAb). Don’t miss this opportunity to leverage our extensive knowledge and enhance your drug development process.
Development of a site-specific and versatile conjugation approach based on bacterial transglutaminase and the Diels-Alder cycloaddition reaction for ADCs
This presentation will focus on the development of a novel two-step conjugation approach that combines the site specificity of the transglutaminase reaction with the reliability of the well-known Diels-Alder reaction to improve deliverability.
Attendees will gain insight into:
Presenter: Francisco Velazquez, PhD, Sr. Director, Chemistry, Abzena